Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Eunsung Jun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5619-2430; OpenAlex author ID A5076943605, A5153263558. Sources: OpenAlex.

Their work

Papers
40 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 9 papers · 2022: 5 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 6 papers

Papers 40

  1. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … Co-author DOI 10.1007/s00464-025-12452-3↗
  2. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreat… Co-author DOI 10.1016/j.surg.2026.110088↗
  3. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  4. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  5. Clinical Utility of Circulating Tumor DNA Analysis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/11795549261480247↗
  6. Combined Gemcitabine and Nab-Paclitaxel Treatment Restores Gut Microbiota Homeostasis in an Orthotopic Pancreatic Ductal Adenocarcinoma Mouse Model. Last author DOI 10.4143/crt.2026.0409↗
  7. Cancer-Specific and Pro-Apoptotic PEGylated Liposomes Containing SMAC-Mimetic Doxorubicin Prodrug for Safe High-Dose Delivery in Pancreatic Cancer. Co-author DOI 10.1002/adhm.202502018↗
  8. Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natural killer cells in pancreatic cancer. First author DOI 10.1016/j.biopha.2025.118714↗
  9. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Co-author DOI 10.1016/j.surg.2025.109331↗
  10. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2023.09.050↗
  11. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  12. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1097/js9.0000000000001927↗
  13. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  14. Orthotopic model of pancreatic cancer using CD34+ humanized mice and generation of tumor organoids from humanized tumors. Last author DOI 10.1016/j.intimp.2023.110451↗
  15. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  16. Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer. Co-author DOI 10.1038/s41525-022-00333-w↗
  17. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  18. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  19. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10641-7↗
  20. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  21. Imaging Strategy that Achieves Ultrahigh Contrast by Utilizing Differential Esterase Activity in Organs: Application in Early Detection of Pancreatic Cancer. Co-author DOI 10.1021/acsnano.1c05165↗
  22. Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor. Co-author DOI 10.1038/s12276-021-00582-2↗
  23. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  24. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  25. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Co-author DOI 10.3390/biomedicines9101291↗
  26. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Co-author DOI 10.3390/biomedicines9111599↗
  27. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Co-author DOI 10.3390/biomedicines9111706↗
  28. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗
  29. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2020.07.016↗
  30. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  31. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  32. Diversity in the Extracellular Vesicle-Derived Microbiome of Tissues According to Tumor Progression in Pancreatic Cancer. Last author DOI 10.3390/cancers12092346↗
  33. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  34. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2019.01354↗
  35. The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target. Co-author DOI 10.3390/cancers11101477↗
  36. Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. Co-author DOI 10.18632/oncotarget.23567↗
  37. Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. Co-author DOI 10.1038/s41598-017-12670-3↗
  38. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Co-author DOI 10.18632/oncotarget.14901↗
  39. Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model. Co-author DOI 10.18632/oncotarget.17370↗
  40. Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma. Co-author PMID 26851005↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Song Cheol Kim · 33 shared papers, 2016–2026 · strength 4.48
  2. Dae Wook Hwang · 18 shared papers, 2017–2026 · strength 3.04
  3. Ki Byung Song · 17 shared papers, 2017–2026 · strength 2.73
  4. Woohyung Lee · 16 shared papers, 2020–2026 · strength 2.66
  5. Yejong Park · 15 shared papers, 2020–2026 · strength 2.53
  6. Min Kyu Sung · 5 shared papers, 2021–2025 · strength 0.88
  7. Joon Oh Park · 6 shared papers, 2020–2026 · strength 0.83
  8. Ajay Goel · 5 shared papers, 2022–2026 · strength 0.82
  9. Daniel D. Von Hoff · 5 shared papers, 2022–2026 · strength 0.82
  10. Jaewoo Kwon · 7 shared papers, 2020–2021 · strength 0.82
  11. John S. Bolton · 4 shared papers, 2022–2026 · strength 0.70
  12. Erkut Hasan Borazanci · 4 shared papers, 2022–2026 · strength 0.70
  13. In Kyong Shim · 6 shared papers, 2016–2023 · strength 0.53
  14. Derek Cridebring · 3 shared papers, 2022–2026 · strength 0.50
  15. Scott A. Celinski · 3 shared papers, 2022–2026 · strength 0.50
  16. Carlos Roberto Becerra · 3 shared papers, 2022–2026 · strength 0.50
  17. Haiyong Han · 3 shared papers, 2022–2026 · strength 0.50
  18. Seung‐Mo Hong · 4 shared papers, 2016–2026 · strength 0.49
  19. Ji Hye Jeong · 2 shared papers, 2023–2025 · strength 0.45
  20. Bong Jun Kwak · 3 shared papers, 2021–2024 · strength 0.45
  21. In Woong Han · 4 shared papers, 2020–2023 · strength 0.43
  22. Seok‐Ho Kim · 4 shared papers, 2019–2021 · strength 0.41
  23. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  24. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.39
  25. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.